STCH Activators
STCH activators can be broadly classified into two categories. The first category includes compounds that indirectly enhance STCH activity by disrupting the function of other heat shock proteins, specifically Hsp90. These compounds, such as Geldanamycin, 17-AAG, and Radicicol, are known to inhibit Hsp90, leading to the disruption of the Hsp90-Cdc37 chaperone complex. This disruption results in the compensatory activation of other heatshock proteins, including STCH, to maintain cellular homeostasis under stress conditions. Consequently, these compounds indirectly enhance STCH activity by triggering the heat shock response, a cellular defense mechanism against protein-damaging stressors. Puromycin falls into this category as well, as it induces the heat shock response, leading to the activation of various heat shock proteins including STCH.
The second category includes compounds that enhance STCH activity via their effects on autophagy. Autophagy is a cellular process that helps in maintaining cellular homeostasis by removing damaged organelles and proteins. Autophagy can be upregulated by inhibiting mTOR kinase, as seen with compounds such as AZD-8055, Torin 1, and Rapamycin. Upregulation of autophagy, in turn, enhances the activity of STCH, given its involvement in the autophagy-lysosome pathway. MG-132, a proteasome inhibitor, also enhances STCH activity by triggering a compensatory increase in autophagy upon proteasome inhibition. Bafilomycin A1 and Chloroquine, both disruptors of lysosomal acidification, indirectly enhance STCH activity by causing an upregulation of autophagy. Lastly, 3-MA and Spautin-1, despite being autophagy inhibitors, can also enhance STCH activity indirectly by disrupting autophagic flux and causing a compensatory upregulation of other elements in the pathway.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin is a benzoquinone ansamycin antibiotic that acts as a potent Hsp90 inhibitor. By inhibiting Hsp90, it disrupts the Hsp90-Cdc37 chaperone complex, which indirectly enhances the activity of STCH as part of the heat shock protein family. This is because their functions are inversely related; when Hsp90 is inhibited, other heat shock proteins including STCH are activated to compensate. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG is a derivative of geldanamycin that also inhibits Hsp90. It disrupts the Hsp90-Cdc37 complex, which indirectly enhances the activity of STCH. The compensatory activation of STCH occurs due to its role within the heat shock protein family when Hsp90 is inhibited. | ||||||
Radicicol | 12772-57-5 | sc-200620 sc-200620A | 1 mg 5 mg | $92.00 $333.00 | 13 | |
Radicicol is an antifungal antibiotic that acts as an Hsp90 inhibitor. By inhibiting Hsp90, it disrupts the Hsp90-Cdc37 complex, leading to enhanced activity of STCH. The increased activity of STCH is a compensatory mechanism due to its role within the heat shock protein family when Hsp90 is inhibited. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $166.00 $322.00 | 436 | |
Puromycin is an aminonucleoside antibiotic that can induce heat shock response. This response leads to the activation of various heat shock proteins, including STCH. Thus, puromycin indirectly enhances STCH activity by triggering the heat shock response. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD-8055 is a selective inhibitor of mTOR kinase. The inhibition of mTOR leads to an upregulation of autophagy, which in turn can enhance the activity of STCH as it is involved in the autophagy-lysosome pathway. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin1 is another selective inhibitor of mTOR. By inhibiting mTOR, it upregulates autophagy. This indirectly enhances the activity of STCH due to its role in the autophagy-lysosome pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an inhibitor of mTOR. Its inhibition of mTOR leads to an upregulation of autophagy, and this process enhances the activity of STCH due to its involvement in the autophagy-lysosome pathway. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor. By inhibiting the proteasome, it triggers a compensatory increase in autophagy, which enhances the activity of STCH due to its role in the autophagy-lysosome pathway. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar type H+-ATPase (V-ATPase). By inhibiting V-ATPase, it disrupts lysosomal acidification, leading to an upregulation of autophagy. This indirectly enhances the activity of STCH as it is involved in the autophagy-lysosome pathway. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is an agent in research used to prevent and treat malaria, and it inhibits lysosomal acidification. This inhibition leads to an upregulation of autophagy, which enhances the activity of STCH due to its role in the autophagy-lysosome pathway. | ||||||